Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v7-FR | Version v1-EN | |
|---|---|---|
| Language (Changed) | Updated to: French | Was: English |
| Date Updated (Changed) | Updated to: 2026-01-19 | Was: 2025-12-03 |
| Drug Identification Number | 02241356 | 02241356 |
| Brand name | IFEX | IFEX |
| Common or Proper name | Ifosfamide | Ifosfamide |
| Company Name | BAXTER CORPORATION | BAXTER CORPORATION |
| Ingredients | IFOSFAMIDE | IFOSFAMIDE |
| Strength(s) | 3G | 3G |
| Dosage form(s) | POWDER FOR SOLUTION | POWDER FOR SOLUTION |
| Route of administration | INTRAVENOUS INTRAVENOUS | INTRAVENOUS INTRAVENOUS |
| Packaging size | 3000 mg | 3000 mg |
| Additional packaging sizes | ||
| ATC code | L01AA | L01AA |
| ATC description | ALKYLATINGAGENTS | ALKYLATINGAGENTS |
| Reason for shortage | Shortage of an active ingredient. | Shortage of an active ingredient. |
| Anticipated start date (Changed) | Updated to: 2025-12-19 | Was: 2026-02-08 |
| Actual start date (Changed) | Updated to: 2025-12-19 | Was: |
| Estimated end date (Changed) | Updated to: 2026-05-01 | Was: Unknown |
| Actual end date | ||
| Shortage status (Changed) | Updated to: Actual shortage | Was: Anticipated shortage |
| Tier 3 Status (Changed) | Updated to: Yes | Was: No |
| Company comments (Changed) | Updated to: Ifex (3g) is currently on 50% allocation. Foreign-labelled product has been approved for import. Once imported and ready to be released, foreign-labelled Ifex (3g) will be available for purchase. | Was: |
| Health Canada comments |